Aurobindo Pharma will catalize your investment surely
Scrip is at Rs 691 having risen handsomely with good volumes after a full fledged correction and hibernating for quite some time.
With USFDA behind it and a good number of ANDAs in the offing and due for sanction from USFDA in the coming year, it is sure to catapult to much newer heights.
Resistance being at Rs 725 ~ 750, a breather and then a sustained rise to Rs 1050+ cannot be ruled out.
Buy and hold with a stoploss of Rs. 665 or so.
With USFDA behind it and a good number of ANDAs in the offing and due for sanction from USFDA in the coming year, it is sure to catapult to much newer heights.
Resistance being at Rs 725 ~ 750, a breather and then a sustained rise to Rs 1050+ cannot be ruled out.
Buy and hold with a stoploss of Rs. 665 or so.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.